TD-HP610016

Simtuzumab(TD-HP610016) is a research-grade recombinant antibody targetingLOXL2. Produced in mammalian cells with native-like glycosylation.HighlightsResearch Grade— For PK/PD studies, assay development, and ADA research.Native Glycosylation— Mammalian expression ensures native-like patterns.

Human

ELISA, Bioactivity: FACS, Functional assay, Research in vivo

Humanized

IgG4-kappa

Monoclonal

LOXL2, Lysyl oxidase-related protein WS9-14, Lysyl oxidase homolog 2, Lysyl oxidase-like protein 2, Lysyl oxidase-related protein 2

Please contact the lab for this information.

>95% purity as determined by SDS-PAGE.

Protein A/G purified from cell culture supernatant.

Q9Y4K0

Liquid

0.01M PBS, pH 7.4.Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.

AB0024, GS-6624, 1318075-13-6

Simtuzumab (AB 0024; GS 6624) is a monoclonal antibody directed against Lysyl oxidase like-2 (LOXL2). Simtuzumab can be used for the research of primary sclerosing cholangitis (PSC).• Lysyl Oxidase (LOX) Family Members: Rationale and Their Potential as Therapeutic Targets for Liver Fibrosis., PMID:32176358• Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma., PMID:35428659• RNA-binding protein RPS7 promotes hepatocellular carcinoma progression via LOXL2-dependent activation of ITGB1/FAK/SRC signaling., PMID:38326908• Human lysyl oxidase-like 2., PMID:25146937• Lysyl oxidase-like 2 (LOXL2)-mediated cross-linking of tropoelastin., PMID:30676771• HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment., PMID:28449718• Lysyl oxidase-like 2 (LOXL2) controls tumor-associated cell proliferation through the interaction with MARCKSL1., PMID:24863880• LOXL2 in Cancer: A Two-Decade Perspective., PMID:37762708• LOXL2-induced PEAR1 Ser891 phosphorylation suppresses CD44 degradation and promotes triple-negative breast cancer metastasis., PMID:39145451• Levoleucovorin inhibits LOXL2 (lysyl oxidase like-2) to control breast cancer proliferation: a repurposing approach., PMID:37340696

SEC-HPLC detection for Research Grade Simtuzumab.　　|　Detects LOXL2 in indirect ELISAs.　　|　SDS-PAGE for Research Grade Simtuzumab.

For research use only. Not suitable for clinical or therapeutic use.